Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation.


Journal Article (Review)

Some believe that tyrosine kinase inhibitor (TKI) therapy is as close to perfect as it gets in oncologic therapy. Patients diagnosed with chronic myeloid leukemia (CML) are treated with a daily oral therapy, through which most achieve remission. TKI therapy is not associated with classic chemotherapy side effects, and most patients are able to resume their normal activities of daily living. Moreover, recent data has demonstrated that CML does not affect the life expectancy of patients whose disease is well controlled with a TKI. However, TKI therapy is actually not that perfect. Patients need to stay on therapy forever. They have to remember to take their medications daily. TKIs are expensive, and the financial burden to patient and society cannot be overstated. Most patients' health-related quality of life is affected; common side effects include fatigue, muscle cramps, pain, edema, skin problems, and gastrointestinal symptoms. In addition, concerns about long-term side effects remain. Recently several studies have shown the feasibility and safety of discontinuation in a select group of patients. Herein, we will review the currently available data on stopping TKIs in CML.

Full Text

Duke Authors

Cited Authors

  • Narra, RK; Flynn, KE; Atallah, E

Published Date

  • October 2017

Published In

Volume / Issue

  • 12 / 5

Start / End Page

  • 415 - 423

PubMed ID

  • 28944397

Pubmed Central ID

  • 28944397

Electronic International Standard Serial Number (EISSN)

  • 1558-822X

Digital Object Identifier (DOI)

  • 10.1007/s11899-017-0404-z


  • eng

Conference Location

  • United States